{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T21:15:14Z","timestamp":1770498914682,"version":"3.49.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science London","doi-asserted-by":"publisher","award":["23K11528"],"award-info":[{"award-number":["23K11528"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Global warming is a known risk factor for chronic kidney disease (CKD), and both progression of the disease and its treatment place a burden on the environment. Life cycle assessment (LCA) is an established method for evaluating the global impact of manufactured products, from materials\u2019 procurement to disposal. We aimed to examine available reports of its application to pharmaceuticals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A narrative review focused on LCA studies of any pharmaceuticals according to disease area.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We identified the drug types used for treatment of 13 disease areas described in 51 previous LCA studies, classified using the MIDAS database. Among the drug types, anesthetics, inhalants, and antibiotics have received the most attention. However, LCA studies are lacking for the wide range of pharmaceuticals used in kidney healthcare, in the fields of dialysis therapy, treatment of end-stage kidney disease, and associated cardiovascular, metabolic, and endocrine diseases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>As the proportion of the population affected by CKD increases, there is a particular urgency for LCA research into drugs administered for their kidney protective effects, such as renin-\u2013angiotensin system inhibitors and sodium-glucose cotransporter 2 inhibitors. As sustainable practices in drug production and the ability to identify and choose effective drugs with low environmental impact require comprehensive LCA data, clinical physicians and pharmacists involved in kidney healthcare should collaborate with pharmaceutical companies to develop an LCA research system .<\/jats:p>\n            <jats:p>Incorporating rating of environmental burden of each drug into daily practice is desirable for achieving sustainable kidney healthcare and reducing its environmental impacts.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10157-025-02647-2","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T20:14:18Z","timestamp":1742415258000},"page":"702-710","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Need for life cycle assessment of pharmaceuticals for kidney healthcare"],"prefix":"10.1007","volume":"29","author":[{"given":"Kei","family":"Nagai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Nansai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"issue":"5","key":"2647_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41581-019-0245-1","volume":"16","author":"KA Barraclough","year":"2020","unstructured":"Barraclough KA, Agar JWM. Green nephrology. Nat Rev Nephrol. 2020;16(5):257\u201368. https:\/\/doi.org\/10.1038\/s41581-019-0245-1.","journal-title":"Nat Rev Nephrol"},{"key":"2647_CR2","doi-asserted-by":"publisher","unstructured":"Watts N, Adger WN, Agnolucci P, Blackstock J, Byass P, Cai W, et al. Health and climate change: policy responses to protect public health. Lancet. 2015;386(10006):1861\u2013914. Epub 2015\/06\/27. https:\/\/doi.org\/10.1016\/s0140-6736(15)60854-6.","DOI":"10.1016\/s0140-6736(15)60854-6"},{"key":"2647_CR3","doi-asserted-by":"publisher","unstructured":"Johnson RJ, Wesseling C, Newman LS. Chronic kidney disease of unknown cause in agricultural communities. N Engl J Med. 2019;380(19):1843\u201352. Epub 2019\/05\/09. https:\/\/doi.org\/10.1056\/NEJMra1813869.","DOI":"10.1056\/NEJMra1813869"},{"issue":"1","key":"2647_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s41100-021-00360-w","volume":"7","author":"K Nagai","year":"2021","unstructured":"Nagai K, Barraclough K, Ueda A, Itsubo N. Sustainability in dialysis therapy: Japanese local and global challenge. Ren Replace Ther. 2021;7(1):42. https:\/\/doi.org\/10.1186\/s41100-021-00360-w.","journal-title":"Ren Replace Ther"},{"issue":"2","key":"2647_CR5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/sdi.12324","volume":"28","author":"JWM Agar","year":"2015","unstructured":"Agar JWM. Green dialysis: the environmental challenges ahead. Semin Dial. 2015;28(2):186\u201392. https:\/\/doi.org\/10.1111\/sdi.12324.","journal-title":"Semin Dial"},{"key":"2647_CR6","doi-asserted-by":"publisher","first-page":"100294","DOI":"10.1016\/j.joclim.2023.100294","volume":"15","author":"K Nagai","year":"2024","unstructured":"Nagai K, Hata S, Itsubo N, Iseki K, Yamagata K, Nansai K. Carbon footprints by stage of chronic kidney disease: the case of Japan. J Clim Change Health. 2024;15:100294. https:\/\/doi.org\/10.1016\/j.joclim.2023.100294.","journal-title":"J Clim Change Health"},{"issue":"2","key":"2647_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1065\/lca2006.02.002","volume":"11","author":"M Finkbeiner","year":"2006","unstructured":"Finkbeiner M, Inaba A, Tan R, Christiansen K, Kl\u00fcppel H-J. The new international standards for life cycle assessment: ISO 14040 and ISO 14044. Int J Life Cycle Assess. 2006;11(2):80\u20135. https:\/\/doi.org\/10.1065\/lca2006.02.002.","journal-title":"Int J Life Cycle Assess"},{"key":"2647_CR8","doi-asserted-by":"publisher","unstructured":"Nagai K, Barraclough K, Matsuo N, Ueda A, Kuno T, Shishido K, et al. A survey of environmental sustainability in Japanese dialysis facilities. Clin Exp Nephrol. 2024;28(6):581\u20137. Epub 2024\/02\/25. https:\/\/doi.org\/10.1007\/s10157-024-02463-0.","DOI":"10.1007\/s10157-024-02463-0"},{"key":"2647_CR9","doi-asserted-by":"publisher","unstructured":"Chen M, Zhou R, Du C, Meng F, Wang Y, Wu L, et al. The carbon footprints of home and in-center peritoneal dialysis in China. Int Urol Nephrol. 2017;49(2):337\u201343. Epub 2016\/11\/17. https:\/\/doi.org\/10.1007\/s11255-016-1418-5.","DOI":"10.1007\/s11255-016-1418-5"},{"key":"2647_CR10","doi-asserted-by":"publisher","unstructured":"McAlister S, Talbot B, Knight J, Blair S, McGain F, McDonald S, et al. The carbon footprint of peritoneal dialysis in Australia. J Am Soc Nephrol. 2024;35(8):1095\u2013103. Epub 2024\/04\/27. https:\/\/doi.org\/10.1681\/asn.0000000000000361.","DOI":"10.1681\/asn.0000000000000361"},{"key":"2647_CR11","doi-asserted-by":"publisher","unstructured":"Nagai K, Itsubo N. Environmental impact of care for end-stage kidney disease on the earth and humans. JMA J. 2022;5(1):109\u201313. Epub 2022\/03\/01. https:\/\/doi.org\/10.31662\/jmaj.2021-0105.","DOI":"10.31662\/jmaj.2021-0105"},{"key":"2647_CR12","doi-asserted-by":"publisher","unstructured":"Connor A, Lillywhite R, Cooke MW. The carbon footprint of a renal service in the United Kingdom. QJM. 2010;103(12):965\u201375. Epub 2010\/08\/20. https:\/\/doi.org\/10.1093\/qjmed\/hcq150.","DOI":"10.1093\/qjmed\/hcq150"},{"key":"2647_CR13","doi-asserted-by":"publisher","unstructured":"Lim AE, Perkins A, Agar JW. The carbon footprint of an Australian satellite haemodialysis unit. Aust Health Rev. 2013;37(3):369\u201374. Epub 2013\/06\/05. https:\/\/doi.org\/10.1071\/ah13022.","DOI":"10.1071\/ah13022"},{"key":"2647_CR14","doi-asserted-by":"publisher","unstructured":"Connor A, Lillywhite R, Cooke MW. The carbon footprints of home and in-center maintenance hemodialysis in the United Kingdom. Hemodial Int. 2011;15(1):39\u201351. Epub 2011\/01\/15. https:\/\/doi.org\/10.1111\/j.1542-4758.2010.00523.x.","DOI":"10.1111\/j.1542-4758.2010.00523.x"},{"key":"2647_CR15","doi-asserted-by":"publisher","unstructured":"Sehgal AR, Slutzman JE, Huml AM. Sources of variation in the carbon footprint of hemodialysis treatment. J Am Soc Nephrol. 2022;33(9):1790\u20135. Epub 2022\/06\/03. https:\/\/doi.org\/10.1681\/asn.2022010086.","DOI":"10.1681\/asn.2022010086"},{"key":"2647_CR16","doi-asserted-by":"publisher","first-page":"135480","DOI":"10.1016\/j.jclepro.2022.135480","volume":"384","author":"MT Hern\u00e1ndez-de-Anda","year":"2023","unstructured":"Hern\u00e1ndez-de-Anda MT, Taboada-Gonz\u00e1lez P, Aguilar-Virgen Q, Velarde-S\u00e1nchez M, M\u00e1rquez-Benavides L. Environmental impacts of a Mexican hemodialysis unit through LCA. J Clean Prod. 2023;384:135480. https:\/\/doi.org\/10.1016\/j.jclepro.2022.135480.","journal-title":"J Clean Prod"},{"issue":"6","key":"2647_CR17","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s10098-022-02283-4","volume":"24","author":"\u00c7E G\u00fcne\u015f","year":"2022","unstructured":"G\u00fcne\u015f \u00c7E, \u015eeng\u00fcl H. Cradle-to-gate life cycle assessment of a liquid pharmaceutical product through analysis of chemical production pathways. Clean Technol Environ Policy. 2022;24(6):1741\u201355. https:\/\/doi.org\/10.1007\/s10098-022-02283-4.","journal-title":"Clean Technol Environ Policy"},{"key":"2647_CR18","doi-asserted-by":"publisher","first-page":"142550","DOI":"10.1016\/j.jclepro.2024.142550","volume":"459","author":"Z Chen","year":"2024","unstructured":"Chen Z, Lian JZ, Zhu H, Zhang J, Zhang Y, Xiang X, et al. Application of life cycle assessment in the pharmaceutical industry: a critical review. J Clean Prod. 2024;459:142550. https:\/\/doi.org\/10.1016\/j.jclepro.2024.142550.","journal-title":"J Clean Prod"},{"key":"2647_CR19","doi-asserted-by":"publisher","first-page":"103100","DOI":"10.1016\/j.copbio.2024.103100","volume":"87","author":"D Etit","year":"2024","unstructured":"Etit D, Meramo S, \u00d6gmundarson \u00d3, Jensen MK, Sukumara S. Can biotechnology lead the way toward a sustainable pharmaceutical industry? Curr Opin Biotechnol. 2024;87:103100. https:\/\/doi.org\/10.1016\/j.copbio.2024.103100.","journal-title":"Curr Opin Biotechnol"},{"issue":"17","key":"2647_CR20","doi-asserted-by":"publisher","first-page":"6510","DOI":"10.1021\/acssuschemeng.2c06518","volume":"11","author":"Y Tao","year":"2023","unstructured":"Tao Y, Zhu S, Smith J, Lakhani N, You F. Environmental sustainability of the globalized pharmaceutical supply chains: the case of tenofovir disoproxil fumarate. ACS Sustain Chem Eng. 2023;11(17):6510\u201322. https:\/\/doi.org\/10.1021\/acssuschemeng.2c06518.","journal-title":"ACS Sustain Chem Eng"},{"issue":"2","key":"2647_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/csr.36","volume":"10","author":"AM de Jonge","year":"2003","unstructured":"de Jonge AM. Limited LCAs of pharmaceutical products: merits and limitations of an environmental management tool. Corp Soc Responsib Environ Manag. 2003;10(2):78\u201390. https:\/\/doi.org\/10.1002\/csr.36.","journal-title":"Corp Soc Responsib Environ Manag"},{"key":"2647_CR22","doi-asserted-by":"publisher","unstructured":"Tetorou A, Makhatova A, Poulopoulos SG. Photochemical mineralization of Ibuprofen medicinal product by means of UV, hydrogen peroxide, titanium dioxide and iron. Water Sci Technol. 2019;80(11):2200\u20135. Epub 2020\/03\/22. https:\/\/doi.org\/10.2166\/wst.2020.041.","DOI":"10.2166\/wst.2020.041"},{"issue":"12","key":"2647_CR23","doi-asserted-by":"publisher","first-page":"6657","DOI":"10.3390\/su13126657","volume":"13","author":"B Fulford","year":"2021","unstructured":"Fulford B, Mezzi K, Whiting A, Aum\u00f4nier S. Life-cycle assessment of the Breezhaler\u00ae breath-actuated dry powder inhaler. Sustainability. 2021;13(12):6657. https:\/\/doi.org\/10.3390\/su13126657.","journal-title":"Sustainability"},{"issue":"5","key":"2647_CR24","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s11367-009-0081-9","volume":"14","author":"S Kim","year":"2009","unstructured":"Kim S, Jim\u00e9nez-Gonz\u00e1lez C, Dale BE. Enzymes for pharmaceutical applications\u2014a cradle-to-gate life cycle assessment. Int J Life Cycle Assess. 2009;14(5):392\u2013400. https:\/\/doi.org\/10.1007\/s11367-009-0081-9.","journal-title":"Int J Life Cycle Assess"},{"issue":"2","key":"2647_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0959-6526(98)00075-4","volume":"7","author":"G J\u00f6dicke","year":"1999","unstructured":"J\u00f6dicke G, Zenklusen O, Weidenhaupt A, Hungerb\u00fchler K. Developing environmentally-sound processes in the chemical industry: a case study on pharmaceutical intermediates. J Clean Prod. 1999;7(2):159\u201366. https:\/\/doi.org\/10.1016\/S0959-6526(98)00075-4.","journal-title":"J Clean Prod"},{"issue":"2","key":"2647_CR26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1039\/C5RE00048C","volume":"1","author":"P Yaseneva","year":"2016","unstructured":"Yaseneva P, Hodgson P, Zakrzewski J, Fal\u00df S, Meadows RE, Lapkin AA. Continuous flow Buchwald-Hartwig amination of a pharmaceutical intermediate. React Chem Eng. 2016;1(2):229\u201338. https:\/\/doi.org\/10.1039\/C5RE00048C.","journal-title":"React Chem Eng"},{"issue":"18","key":"2647_CR27","doi-asserted-by":"publisher","first-page":"15247","DOI":"10.1021\/acssuschemeng.9b02238","volume":"7","author":"B Riazi","year":"2019","unstructured":"Riazi B, Zhang J, Yee W, Ngo H, Spatari S. Life cycle environmental and cost implications of isostearic acid production for pharmaceutical and personal care products. ACS Sustain Chem Eng. 2019;7(18):15247\u201358. https:\/\/doi.org\/10.1021\/acssuschemeng.9b02238.","journal-title":"ACS Sustain Chem Eng"},{"issue":"6","key":"2647_CR28","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1039\/C3GC42513D","volume":"16","author":"A Amelio","year":"2014","unstructured":"Amelio A, Genduso G, Vreysen S, Luis P, Van der Bruggen B. Guidelines based on life cycle assessment for solvent selection during the process design and evaluation of treatment alternatives. Green Chem. 2014;16(6):3045\u201363. https:\/\/doi.org\/10.1039\/C3GC42513D.","journal-title":"Green Chem"},{"issue":"10","key":"2647_CR29","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1039\/C003666H","volume":"12","author":"MJ Raymond","year":"2010","unstructured":"Raymond MJ, Slater CS, Savelski MJ. LCA approach to the analysis of solvent waste issues in the pharmaceutical industry. Green Chem. 2010;12(10):1826\u201334. https:\/\/doi.org\/10.1039\/C003666H.","journal-title":"Green Chem"},{"issue":"10","key":"2647_CR30","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1007\/s10098-017-1444-8","volume":"19","author":"MJ Savelski","year":"2017","unstructured":"Savelski MJ, Slater CS, Tozzi PV, Wisniewski CM. On the simulation, economic analysis, and life cycle assessment of batch-mode organic solvent recovery alternatives for the pharmaceutical industry. Clean Technol Environ Policy. 2017;19(10):2467\u201377. https:\/\/doi.org\/10.1007\/s10098-017-1444-8.","journal-title":"Clean Technol Environ Policy"},{"issue":"11","key":"2647_CR31","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1021\/acs.oprd.6b00275","volume":"20","author":"CK Lee","year":"2016","unstructured":"Lee CK, Khoo HH, Tan RBH. Life cyle assessment based environmental performance comparison of batch and continuous processing: a case of 4-d-erythronolactone synthesis. Org Process Res Dev. 2016;20(11):1937\u201348. https:\/\/doi.org\/10.1021\/acs.oprd.6b00275.","journal-title":"Org Process Res Dev"},{"issue":"11","key":"2647_CR32","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1021\/op5000573","volume":"18","author":"I Den\u010di\u0107","year":"2014","unstructured":"Den\u010di\u0107 I, Ott D, Kralisch D, No\u00ebl T, Meuldijk J, de Croon M, et al. Eco-efficiency analysis for intensified production of an active pharmaceutical ingredient: a case study. Org Process Res Dev. 2014;18(11):1326\u201338. https:\/\/doi.org\/10.1021\/op5000573.","journal-title":"Org Process Res Dev"},{"issue":"2","key":"2647_CR33","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/BF02978570","volume":"9","author":"C Jim\u00e9nez-Gonz\u00e1lez","year":"2004","unstructured":"Jim\u00e9nez-Gonz\u00e1lez C, Curzons AD, Constable DJC, Cunningham VL. Cradle-to-gate life cycle inventory and assessment of pharmaceutical compounds. Int J Life Cycle Assess. 2004;9(2):114\u201321. https:\/\/doi.org\/10.1007\/BF02978570.","journal-title":"Int J Life Cycle Assess"},{"issue":"12","key":"2647_CR34","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1002\/cssc.201402313","volume":"7","author":"D Ott","year":"2014","unstructured":"Ott D, Kralisch D, Den\u010di\u0107 I, Hessel V, Laribi Y, Perrichon PD, et al. Life cycle analysis within pharmaceutical process optimization and intensification: case study of active pharmaceutical ingredient production. Chemsuschem. 2014;7(12):3521\u201333. https:\/\/doi.org\/10.1002\/cssc.201402313.","journal-title":"Chemsuschem"},{"issue":"13","key":"2647_CR35","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1080\/10934529.2013.815080","volume":"48","author":"CS Slater","year":"2013","unstructured":"Slater CS, Savelski MJ, Ruiz-Felix MN. Life cycle analysis of solvent reduction in pharmaceutical synthesis using continuous adsorption for palladium removal. J Environ Sci Health Part A. 2013;48(13):1602\u20138. https:\/\/doi.org\/10.1080\/10934529.2013.815080.","journal-title":"J Environ Sci Health Part A"},{"issue":"7","key":"2647_CR36","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1021\/es1015907","volume":"45","author":"G Van der Vorst","year":"2011","unstructured":"Van der Vorst G, Dewulf J, Aelterman W, De Witte B, Van Langenhove H. A systematic evaluation of the resource consumption of active pharmaceutical ingredient production at three different levels. Environ Sci Technol. 2011;45(7):3040\u20136. https:\/\/doi.org\/10.1021\/es1015907.","journal-title":"Environ Sci Technol"},{"issue":"3","key":"2647_CR37","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s11367-010-0151-z","volume":"15","author":"G Wernet","year":"2010","unstructured":"Wernet G, Conradt S, Isenring HP, Jim\u00e9nez-Gonz\u00e1lez C, Hungerb\u00fchler K. Life cycle assessment of fine chemical production: a case study of pharmaceutical synthesis. Int J Life Cycle Assess. 2010;15(3):294\u2013303. https:\/\/doi.org\/10.1007\/s11367-010-0151-z.","journal-title":"Int J Life Cycle Assess"},{"key":"2647_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.fbp.2019.08.003","volume":"118","author":"KC Teh","year":"2019","unstructured":"Teh KC, Tan RR, Aviso KB, Promentilla MAB, Tan J. An integrated analytic hierarchy process and life cycle assessment model for nanocrystalline cellulose production. Food Bioprod Process. 2019;118:13\u201331. https:\/\/doi.org\/10.1016\/j.fbp.2019.08.003.","journal-title":"Food Bioprod Process"},{"issue":"5","key":"2647_CR39","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/btpr.2323","volume":"32","author":"P Bunnak","year":"2016","unstructured":"Bunnak P, Allmendinger R, Ramasamy SV, Lettieri P, Titchener-Hooker NJ. Life-cycle and cost of goods assessment of fed-batch and perfusion-based manufacturing processes for mAbs. Biotechnol Prog. 2016;32(5):1324\u201335. https:\/\/doi.org\/10.1002\/btpr.2323.","journal-title":"Biotechnol Prog"},{"key":"2647_CR40","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.nbt.2022.01.002","volume":"68","author":"K Budzinski","year":"2022","unstructured":"Budzinski K, Constable D, D\u2019Aquila D, Smith P, Madabhushi SR, Whiting A, et al. Streamlined life cycle assessment of single use technologies in biopharmaceutical manufacture. New Biotechnol. 2022;68:28\u201336. https:\/\/doi.org\/10.1016\/j.nbt.2022.01.002.","journal-title":"New Biotechnol"},{"key":"2647_CR41","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jclepro.2012.09.048","volume":"41","author":"M Pietrzykowski","year":"2013","unstructured":"Pietrzykowski M, Flanagan W, Pizzi V, Brown A, Sinclair A, Monge M. An environmental life cycle assessment comparison of single-use and conventional process technology for the production of monoclonal antibodies. J Clean Prod. 2013;41:150\u201362. https:\/\/doi.org\/10.1016\/j.jclepro.2012.09.048.","journal-title":"J Clean Prod"},{"key":"2647_CR42","doi-asserted-by":"publisher","first-page":"151565","DOI":"10.1016\/j.scitotenv.2021.151565","volume":"816","author":"F Bassani","year":"2022","unstructured":"Bassani F, Rodrigues C, Marques P, Freire F. Ecodesign approach for pharmaceutical packaging based on life cycle assessment. Sci Total Environ. 2022;816:151565. https:\/\/doi.org\/10.1016\/j.scitotenv.2021.151565.","journal-title":"Sci Total Environ"},{"key":"2647_CR43","unstructured":"IQVIA MIDAS\u00ae. https:\/\/www.iqvia.com\/solutions\/commercialization\/brand-strategy-and-management\/market-measurement\/midas"},{"key":"2647_CR44","doi-asserted-by":"publisher","unstructured":"Sherman J, Le C, Lamers V, Eckelman M. Life cycle greenhouse gas emissions of anesthetic drugs. Anesth Analg. 2012;114(5):1086\u201390. Epub 2012\/04\/12. https:\/\/doi.org\/10.1213\/ANE.0b013e31824f6940.","DOI":"10.1213\/ANE.0b013e31824f6940"},{"key":"2647_CR45","doi-asserted-by":"publisher","first-page":"126074","DOI":"10.1016\/j.jclepro.2021.126074","volume":"292","author":"D Wang","year":"2021","unstructured":"Wang D, Cheow WS, Amalina N, Faiezin M, Hadinoto K. Selecting optimal pharmaceutical excipient formulation from life cycle assessment perspectives: a case study on ibuprofen tablet formulations. J Clean Prod. 2021;292:126074. https:\/\/doi.org\/10.1016\/j.jclepro.2021.126074.","journal-title":"J Clean Prod"},{"issue":"10","key":"2647_CR46","doi-asserted-by":"publisher","first-page":"12446","DOI":"10.1007\/s10668-021-01948-2","volume":"24","author":"RK Sharma","year":"2022","unstructured":"Sharma RK, Raju G, Sarkar P, Singh H, Singla E. Comparing the environmental impacts of paracetamol dosage forms using life cycle assessment. Environ Dev Sustain. 2022;24(10):12446\u201366. https:\/\/doi.org\/10.1007\/s10668-021-01948-2.","journal-title":"Environ Dev Sustain"},{"issue":"6","key":"2647_CR47","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s10098-020-01865-4","volume":"22","author":"RK Sharma","year":"2020","unstructured":"Sharma RK, Sarkar P, Singh H. Assessing the sustainability of a manufacturing process using life cycle assessment technique\u2014a case of an Indian pharmaceutical company. Clean Technol Environ Policy. 2020;22(6):1269\u201384. https:\/\/doi.org\/10.1007\/s10098-020-01865-4.","journal-title":"Clean Technol Environ Policy"},{"issue":"4","key":"2647_CR48","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1039\/c5gc01932j","volume":"18","author":"D Ott","year":"2016","unstructured":"Ott D, Borukhova S, Hessel V. Life cycle assessment of multi-step rufinamide synthesis\u2014from isolated reactions in batch to continuous microreactor networks. Green Chem. 2016;18(4):1096\u2013116. https:\/\/doi.org\/10.1039\/c5gc01932j.","journal-title":"Green Chem"},{"key":"2647_CR49","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.jclepro.2017.02.107","volume":"168","author":"PL Amado Alviz","year":"2017","unstructured":"Amado Alviz PL, Alvarez AJ. Comparative life cycle assessment of the use of an ionic liquid ([Bmim]Br) versus a volatile organic solvent in the production of acetylsalicylic acid. J Clean Prod. 2017;168:1614\u201324. https:\/\/doi.org\/10.1016\/j.jclepro.2017.02.107.","journal-title":"J Clean Prod"},{"key":"2647_CR50","unstructured":"Jim\u00e9nez-Gonz\u00e1lez C. Life cycle assessment in pharmaceutical applications 2000 [Thesis]."},{"key":"2647_CR51","doi-asserted-by":"publisher","unstructured":"McAlister S, Ou Y, Neff E, Hapgood K, Story D, Mealey P, et al. The Environmental footprint of morphine: a life cycle assessment from opium poppy farming to the packaged drug. BMJ Open. 2016;6(10):e013302. Epub 2016\/11\/01. https:\/\/doi.org\/10.1136\/bmjopen-2016-013302.","DOI":"10.1136\/bmjopen-2016-013302"},{"issue":"11","key":"2647_CR52","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1039\/c3gc41185k","volume":"15","author":"W De Soete","year":"2013","unstructured":"De Soete W, Dewulf J, Cappuyns P, Van der Vorst G, Heirman B, Aelterman W, et al. Exergetic sustainability assessment of batch versus continuous wet granulation based pharmaceutical tablet manufacturing: a cohesive analysis at three different levels. Green Chem. 2013;15(11):3039\u201348. https:\/\/doi.org\/10.1039\/c3gc41185k.","journal-title":"Green Chem"},{"issue":"7","key":"2647_CR53","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1021\/acssuschemeng.8b05473","volume":"7","author":"AG Parvatker","year":"2019","unstructured":"Parvatker AG, Tunceroglu H, Sherman JD, Coish P, Anastas P, Zimmerman JB, et al. Cradle-to-gate greenhouse gas emissions for twenty anesthetic active pharmaceutical ingredients based on process scale-up and process design calculations. ACS Sustain Chem Eng. 2019;7(7):6580\u201391. https:\/\/doi.org\/10.1021\/acssuschemeng.8b05473.","journal-title":"ACS Sustain Chem Eng"},{"issue":"2","key":"2647_CR54","doi-asserted-by":"publisher","first-page":"e10043","DOI":"10.1002\/amp2.10043","volume":"2","author":"F Grimaldi","year":"2020","unstructured":"Grimaldi F, de Leon Izeppi GA, Kirschneck D, Lettieri P, Escrib\u00e0-Gelonch M, Hessel V. Life cycle assessment and cost evaluation of emerging technologies at early stages: the case of continuous flow synthesis of rufinamide. J Adv Manuf Process. 2020;2(2):e10043. https:\/\/doi.org\/10.1002\/amp2.10043.","journal-title":"J Adv Manuf Process"},{"key":"2647_CR55","doi-asserted-by":"publisher","first-page":"100329","DOI":"10.1016\/j.scp.2020.100329","volume":"18","author":"M-W Siegert","year":"2020","unstructured":"Siegert M-W, Saling P, Mielke P, Czechmann C, Emara Y, Finkbeiner M. Cradle-to-grave life cycle assessment of an ibuprofen analgesic. Sustain Chem Pharm. 2020;18:100329. https:\/\/doi.org\/10.1016\/j.scp.2020.100329.","journal-title":"Sustain Chem Pharm"},{"issue":"8","key":"2647_CR56","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1007\/s11367-019-01722-7","volume":"25","author":"M-W Siegert","year":"2020","unstructured":"Siegert M-W, Lehmann A, Emara Y, Finkbeiner M. Addressing the use and end-of-life phase of pharmaceutical products in life cycle assessment. Int J Life Cycle Assess. 2020;25(8):1436\u201354. https:\/\/doi.org\/10.1007\/s11367-019-01722-7.","journal-title":"Int J Life Cycle Assess"},{"issue":"10","key":"2647_CR57","doi-asserted-by":"publisher","first-page":"5535","DOI":"10.1021\/es203987b","volume":"46","author":"SM Cook","year":"2012","unstructured":"Cook SM, VanDuinen BJ, Love NG, Skerlos SJ. Life cycle comparison of environmental emissions from three disposal options for unused pharmaceuticals. Environ Sci Technol. 2012;46(10):5535\u201341. https:\/\/doi.org\/10.1021\/es203987b.","journal-title":"Environ Sci Technol"},{"key":"2647_CR58","doi-asserted-by":"publisher","first-page":"f3359","DOI":"10.1136\/bmj.f3359","volume":"346","author":"T Hillman","year":"2013","unstructured":"Hillman T, Mortimer F, Hopkinson NS. Inhaled drugs and global warming: time to shift to dry powder inhalers. BMJ. 2013;346:f3359. https:\/\/doi.org\/10.1136\/bmj.f3359.","journal-title":"BMJ"},{"issue":"5","key":"2647_CR59","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1007\/s11845-022-03234-0","volume":"192","author":"S Owens","year":"2023","unstructured":"Owens S, Morris K, Hurley E, O\u2019Reilly K, O\u2019Callaghan J, Allman J, et al. Estimating the national carbon footprint of inhalers in healthcare. Ir J Med Sci. 2023;192(5):2251\u20133. https:\/\/doi.org\/10.1007\/s11845-022-03234-0.","journal-title":"Ir J Med Sci"},{"issue":"4","key":"2647_CR60","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/antibiotics12040640","volume":"12","author":"SC Walpole","year":"2023","unstructured":"Walpole SC, Eii MN, Lyons T, Aldridge C. Improving antimicrobial use to protect the environment: what is the role of infection specialists? Antibiotics. 2023;12(4):640. https:\/\/doi.org\/10.3390\/antibiotics12040640.","journal-title":"Antibiotics"},{"issue":"15","key":"2647_CR61","doi-asserted-by":"publisher","first-page":"E3463","DOI":"10.1073\/pnas.1717295115","volume":"115","author":"EY Klein","year":"2018","unstructured":"Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci U S A. 2018;115(15):E3463\u201370. https:\/\/doi.org\/10.1073\/pnas.1717295115.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2647_CR62","doi-asserted-by":"publisher","first-page":"105734","DOI":"10.1016\/j.jece.2021.105734","volume":"9","author":"W Kong","year":"2021","unstructured":"Kong W, Lv B, Yang S, Shen H, Jing G, Zhou Z. Case study on environmental safety and sustainability of pharmaceutical production based on life cycle assessment of enrofloxacin. J Environ Chem Eng. 2021;9(4):105734. https:\/\/doi.org\/10.1016\/j.jece.2021.105734.","journal-title":"J Environ Chem Eng"},{"issue":"1","key":"2647_CR63","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11367-020-01841-6","volume":"26","author":"K Yang","year":"2021","unstructured":"Yang K, Lv B, Shen H, Jing G, Zhou Z. Life cycle assessment of pharmaceuticals: the ciprofloxacin hydrochloride case. Int J Life Cycle Assess. 2021;26(1):64\u201375. https:\/\/doi.org\/10.1007\/s11367-020-01841-6.","journal-title":"Int J Life Cycle Assess"},{"key":"2647_CR64","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.spc.2018.05.004","volume":"15","author":"KG Harding","year":"2018","unstructured":"Harding KG, Dennis JS, Harrison STL. Generic flowsheeting approach to generating first estimate material and energy balance data for Life Cycle Assessment (LCA) of Penicillin V production. Sustain Prod Consum. 2018;15:89\u201395. https:\/\/doi.org\/10.1016\/j.spc.2018.05.004.","journal-title":"Sustain Prod Consum"},{"key":"2647_CR65","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jclepro.2014.02.012","volume":"76","author":"R Brunet","year":"2014","unstructured":"Brunet R, Guill\u00e9n-Gos\u00e1lbez G, Jim\u00e9nez L. Combined simulation\u2013optimization methodology to reduce the environmental impact of pharmaceutical processes: application to the production of Penicillin V. J Clean Prod. 2014;76:55\u201363. https:\/\/doi.org\/10.1016\/j.jclepro.2014.02.012.","journal-title":"J Clean Prod"},{"key":"2647_CR66","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.resconrec.2014.08.002","volume":"91","author":"W De Soete","year":"2014","unstructured":"De Soete W, Boone L, Willemse F, De Meyer E, Heirman B, Van Langenhove H, et al. Environmental resource footprinting of drug manufacturing: effects of scale-up and tablet dosage. Resour Conserv Recycl. 2014;91:82\u20138. https:\/\/doi.org\/10.1016\/j.resconrec.2014.08.002.","journal-title":"Resour Conserv Recycl"},{"issue":"2","key":"2647_CR67","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1089\/ind.2008.4.180","volume":"4","author":"RK Henderson","year":"2008","unstructured":"Henderson RK, Jim\u00e9nez-Gonz\u00e1lez C, Preston C, Constable DJC, Woodley JM. Peer review original research: EHS & LCA assessment for 7-ACA synthesis a case study for comparing biocatalytic & chemical synthesis. Ind Biotechnol. 2008;4(2):180\u201392. https:\/\/doi.org\/10.1089\/ind.2008.4.180.","journal-title":"Ind Biotechnol"},{"issue":"6","key":"2647_CR68","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/j.scitotenv.2009.10.057","volume":"408","author":"C Ponder","year":"2010","unstructured":"Ponder C, Overcash M. Cradle-to-gate life cycle inventory of vancomycin hydrochloride. Sci Total Environ. 2010;408(6):1331\u20137. https:\/\/doi.org\/10.1016\/j.scitotenv.2009.10.057.","journal-title":"Sci Total Environ"},{"key":"2647_CR69","doi-asserted-by":"publisher","unstructured":"Polianciuc SI, Gurz\u0103u AE, Kiss B, \u015etefan MG, Loghin F. Antibiotics in the environment: causes and consequences. Med Pharm Rep. 2020;93(3):231\u201340. https:\/\/doi.org\/10.15386\/mpr-1742.","DOI":"10.15386\/mpr-1742"},{"issue":"1670","key":"2647_CR70","doi-asserted-by":"publisher","first-page":"20140083","DOI":"10.1098\/rstb.2014.0083","volume":"370","author":"M Woolhouse","year":"2015","unstructured":"Woolhouse M, Ward M, van Bunnik B, Farrar J. Antimicrobial resistance in humans, livestock and the wider environment. Philos Trans R Soc Lond B Biol Sci. 2015;370(1670):20140083. https:\/\/doi.org\/10.1098\/rstb.2014.0083.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"5","key":"2647_CR71","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41579-021-00649-x","volume":"20","author":"DGJ Larsson","year":"2022","unstructured":"Larsson DGJ, Flach CF. Antibiotic resistance in the environment. Nat Rev Microbiol. 2022;20(5):257\u201369. https:\/\/doi.org\/10.1038\/s41579-021-00649-x.","journal-title":"Nat Rev Microbiol"},{"key":"2647_CR72","doi-asserted-by":"publisher","first-page":"100589","DOI":"10.1016\/j.scp.2021.100589","volume":"25","author":"RAA Schulte","year":"2022","unstructured":"Schulte RAA, Link A, Siegert M-W, Finkbeiner M. Modeling the use and end-of-life phase of pharmaceuticals in support of a life cycle inventory analysis\u2014case study on different antibiotics in Germany. Sustain Chem Pharm. 2022;25:100589. https:\/\/doi.org\/10.1016\/j.scp.2021.100589.","journal-title":"Sustain Chem Pharm"},{"key":"2647_CR73","doi-asserted-by":"publisher","first-page":"159049","DOI":"10.1016\/j.scitotenv.2022.159049","volume":"856","author":"J Sanchez-Matos","year":"2023","unstructured":"Sanchez-Matos J, Regueiro L, Gonz\u00e1lez-Garc\u00eda S, V\u00e1zquez-Rowe I. Environmental performance of rainbow trout (Oncorhynchus mykiss) production in Galicia-Spain: a life cycle assessment approach. Sci Total Environ. 2023;856:159049. https:\/\/doi.org\/10.1016\/j.scitotenv.2022.159049.","journal-title":"Sci Total Environ"},{"key":"2647_CR74","doi-asserted-by":"publisher","first-page":"104525","DOI":"10.1016\/j.resconrec.2019.104525","volume":"152","author":"K Nansai","year":"2020","unstructured":"Nansai K, Fry J, Malik A, Takayanagi W, Kondo N. Carbon footprint of Japanese health care services from 2011 to 2015. Resour Conserv Recycl. 2020;152:104525. https:\/\/doi.org\/10.1016\/j.resconrec.2019.104525.","journal-title":"Resour Conserv Recycl"},{"issue":"3","key":"2647_CR75","doi-asserted-by":"publisher","first-page":"c200","DOI":"10.1159\/000317200","volume":"116","author":"A Connor","year":"2010","unstructured":"Connor A, Mortimer F, Tomson C. Clinical transformation: the key to green nephrology. Nephron Clin Pract. 2010;116(3):c200\u20135. https:\/\/doi.org\/10.1159\/000317200.","journal-title":"Nephron Clin Pract"},{"issue":"1","key":"2647_CR76","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.kint.2022.12.015","volume":"104","author":"CE Stigant","year":"2023","unstructured":"Stigant CE, Barraclough KA, Harber M, Kanagasundaram NS, Malik C, Jha V, et al. Our shared responsibility: the urgent necessity of global environmentally sustainable kidney care. Kidney Int. 2023;104(1):12\u20135. https:\/\/doi.org\/10.1016\/j.kint.2022.12.015.","journal-title":"Kidney Int"},{"issue":"12","key":"2647_CR77","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861\u20139. https:\/\/doi.org\/10.1056\/NEJMoa011161.","journal-title":"N Engl J Med"},{"issue":"15","key":"2647_CR78","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"2","key":"2647_CR79","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","journal-title":"N Engl J Med"},{"issue":"12","key":"2647_CR80","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.2215\/cjn.03790322","volume":"17","author":"P McEwan","year":"2022","unstructured":"McEwan P, Darlington O, Miller R, McMurray JJV, Wheeler DC, Heerspink HJL, et al. Cost-effectiveness of dapagliflozin as a treatment for chronic kidney disease: a health-economic analysis of DAPA-CKD. Clin J Am Soc Nephrol. 2022;17(12):1730\u201341. https:\/\/doi.org\/10.2215\/cjn.03790322.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"2647_CR81","doi-asserted-by":"publisher","first-page":"e1055","DOI":"10.1016\/s2542-5196(24)00281-x","volume":"8","author":"B Talbot","year":"2024","unstructured":"Talbot B, Fletcher RA, Neal B, Oshima M, Adshead F, Moore K, et al. The potential for reducing greenhouse gas emissions through disease prevention: a secondary analysis of data from the CREDENCE trial. Lancet Planet Health. 2024;8(12):e1055\u201364. https:\/\/doi.org\/10.1016\/s2542-5196(24)00281-x.","journal-title":"Lancet Planet Health"},{"key":"2647_CR82","doi-asserted-by":"publisher","unstructured":"Nagai K. Movement toward environmentally friendly pharmaceuticals in Japan. JMA J. 2023;6(4):515\u20139. https:\/\/doi.org\/10.31662\/jmaj.2023-0026.","DOI":"10.31662\/jmaj.2023-0026"},{"key":"2647_CR83","doi-asserted-by":"publisher","unstructured":"Garcia Sanchez JJ, Barraclough KA, Cases A, et al. Using chronic kidney disease as a model framework to estimate healthcare-related environmental impact. Adv Ther. Published online November 14, 2024. https:\/\/doi.org\/10.1007\/s12325-024-03039-w.","DOI":"10.1007\/s12325-024-03039-w"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02647-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-025-02647-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02647-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T05:19:40Z","timestamp":1748582380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-025-02647-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":83,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2647"],"URL":"https:\/\/doi.org\/10.1007\/s10157-025-02647-2","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and informed consent: Because this study did not involve human participants or animals, ethics approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"K. Nagai has received lecture fees from AstraZeneca K.K, Nippon Boehringer Ingelheim Co., Ltd., Mochida Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Kissei Pharmaceutical Co., Ltd., Torii Pharmaceutical Co., Ltd., and Daiichi Sankyo Healthcare Co., Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}